Visual and Patient-Reported Outcomes After Bilateral Non-Diffractive EDOF IOL Implantation
Key facts
- Who runs it
- Benha University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 30 people enrolled
- Started
- 3 Jan 2025
- Ended
- 31 Jan 2025
- Type of study
- Interventional
- Treatments tested
- AcrySof IQ Vivity EDOF Intraocular Lens
- Record updated
- 9 March 2026
Who can take part
- Age
- 40 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age-related cataract requiring bilateral phacoemulsification
- Corneal astigmatism ≤1.0 diopter
- Desire for postoperative spectacle independence
- Age ≥40 years
- Ability and willingness to provide written informed consent
Who cannot take part
- Previous ocular surgery in either eye
- Systemic conditions likely to affect vision or surgical outcomes
- Glaucoma
- Macular degeneration
- Corneal pathology
- Any ocular comorbidity that may affect visual outcomes
- Inability to comply with postoperative follow-up visits or study assessments
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study evaluates visual outcomes and patient-reported satisfaction following bilateral cataract surgery using a non-diffractive extended depth-of-focus (EDOF) intraocular lens (AcrySof IQ Vivity). The purpose of the study is to assess distance, intermediate, and near visual acuity, refractive accuracy, contrast sensitivity, spectacle independence, and the presence of photic phenomena after implantation. Thirty patients undergoing bilateral phacoemulsification will be enrolled. Participants will be evaluated at 1 and 3 months postoperatively.
The group in the trial
- Bilateral Non-Diffractive EDOF IOL ImplantationTreatment being tested
All participants underwent standard bilateral phacoemulsification cataract surgery with implantation of the AcrySof IQ Vivity non-diffractive extended depth-of-focus (EDOF) intraocular lens in both eyes. Target refraction was emmetropia. Postoperative care included a 4-week taper of combined topical antibiotic-steroid drops. Visual acuity, intermediate and near vision, spectacle independence, patient satisfaction, and photic phenomena were assessed at 1 and 3 months postoperatively.
Treatment: AcrySof IQ Vivity EDOF Intraocular Lens
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Visual and Patient-Reported Outcomes Following Bilateral Implantation of Non-Diffractive Extended Depth-of-Focus Intraocular Lenses in Patients Undergoing Cataract Surgery
- Record updated
- 9 March 2026